Industry News
Latest Industry News stories, reviewed before publishing.
Advertise Here
Reach qualified buyersBoost your visibility among pharma sourcing professionals and potential buyers.
- Grow your business with qualified leads
- GDS reports on your ad performance
- Targeted to this product's audience
- Direct enquiries from buyers
- Visibility to pharma professionals
Sun Pharma to present long-term cancer drug data at ESMO 2026
UNLOXCYT was approved by the US Food and Drug Administration (FDA) in 2024 for adults with metastatic or locally advanced cutaneous squamous cell carcinoma
Latest news
Showing 1–12 of 89 stories
Torrent Pharma Profit Falls 9.6 Per Cent, Dr Reddy’s Slumps 36 Pc In Q2 FY27
Torrent Pharmaceuticals’ Q2 FY27 net profit fell 9.6% to Rs 534 crore, although revenue rose 50.8% to Rs 4,979 crore as expenses climbed 70.9%. Dr…
Novo’s Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older…
Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to…
Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older…
Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to…
Roche Pharma Sales Beat Q3 Consensus Forecast by CHF 350 Million
Group sales rose 8% in Swiss francs to CHF 16.13 billion, and Roche kept its 2026 growth outlook.
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® for Adults With Moderately to Severely Active…
Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector…
Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week…
Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today…
Novartis Pharma AG: Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with…
Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years…
Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety…
Basel, October 23, 2026 – Novartis today presented positive results from the pivotal Phase III REMODEL-1 and REMODEL-2 trials in relapsing multiple…
Press Release: Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven…
-- Remibrutinib achieved significant and clinically meaningful reduction in relapses vs. teriflunomide, to approximately 1 relapse every 13 years…
Lupin appoints Brian Savage as President, Chief Legal Officer
He joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015, serving most recently as executive vice…
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in…
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses…
Page 1 of 8
Advertise on PharmaJungle - Free for 30 Days
Get your company in front of buyers, manufacturers, and sourcing professionals on PharmaJungle - completely free for your first 30 days.
- 30 days of free advertising
- Visibility across all pages
- Performance report with ad insights
- No setup or registration fee
Exclusive introductory offer for new advertisers
Top sources
Post your requirement
Get offers from suppliers
- Reach pharmaceutical suppliers
- Specify quality standard and quantity
- Set your shipping preference
- Receive offers directly
- Listed on our marketplace
Your product details and requirements may be published on the marketplace.
Create a New Buying Request
Fields marked with * are mandatory.